The company added that details of the settlement are confidential. In March 2024, a jury found that Dexcom’s G6 glucose monitors infringed one of three of Abbott’s patents, but jurors couldn’t reach a ...

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Dexcom (DXCM – Research Report), with a ...

Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

Dexcom (DXCM) has received a new Buy rating, initiated by Wells Fargo analyst, Larry Biegelsen.Stay Ahead of the Market:Discover outperforming ...

Acton, Massachusetts-based Insulet touts Omnipod 5 as the number one insulin pump for new users in Europe. It remains the top ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...

Its top products include the Dexcom G6 which provides real-time glucose monitoring, Dexcom G7 which is user-friendly and known for its accuracy, Dexcom Share System which allows remote monitoring ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate blood ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...